Global Portal Hypertension Drugs Market
Global Portal Hypertension Drugs Market

Portal Hypertension Drugs Comprehensive Study by Type (Prehepatic, Intrahepatic, Posthepatic), Treatment (Endoscopic Therapy, Surgery, Radiology, Others), Drug Class (Vasoconstrictors, Vasodilators, Propranolol, Isosorbide, Others), End User (Hospital, Clinics, Diagnostics Centres) Players and Region - Global Market Outlook to 2026

Portal Hypertension Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Dec 2021 Edition 249 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Portal Hypertension Drugs Market Overview:
Portal hypertension is defined as an increase in pressure within the portal vein (the vein that carries blood from the digestive organs to the liver). The increase in pressure is caused by a blockage in the blood flow through the liver. Increased pressure in the portal vein causes large veins (varices) to form across the oesophagus and stomach to bypass the blockage. Varices become fragile and bleed easily. Cirrhosis, or liver scarring, is the leading cause of portal hypertension. Cirrhosis develops as a result of the healing of a liver injury caused by hepatitis, alcoholism, or other liver damage. Cirrhosis occurs when scar tissue obstructs blood flow through the liver and slows its processing functions. Thrombosis, or a blood clot that forms in the portal vein, can also cause portal hypertension.

Growth Drivers
  • Rise in Smoking, Alcohol/Tobacco Consumption, and Other Idiopathic Condition
  • Increasing Incidence of Portal Hypertension

Roadblocks
  • Side Effects associated with Portal Hypertension Drugs

Opportunities
  • Increase in Prevalence of Pulmonary Arterial Hypertension
  • Growing Senior Citizen Population

Challenges
  • High Cost of Drug Development


Competitive Landscape:
The demand for Portal Hypertension is increasing. The industry is segmented, but it is predicted to grow as rise in alcohol, smoking consumption and changing lifestyle, among other factors, drive the market forward. Businesses in this sector face global competition from market leaders who control a large share of the market. Companies are differentiating their products from competition by employing environmentally friendly materials and manufacturing techniques. The Leading Players are engaging in strategic global expansion to maintain their Market Position.
Some of the key players profiled in the report are Pfizer (United States), Sanofi (France), Bayer (Germany), Gilead Sciences (United States), Johnson & Johnson (United States), United Therapeutics Corporation (Maryland), Merck & Co (United States), GlaxoSmithKline (United Kingdom), Eli Lilly and Company (United States), AstraZeneca (United Kingdom) and Ono Pharmaceutical (Japan). Additionally, following companies can also be profiled that are part of our coverage like Chiasma (United States) and Acceleron Pharma (United States. Analyst at AMA Research see United States Players to retain maximum share of Global Portal Hypertension Drugs market by 2026. Considering Market by Treatment, the sub-segment i.e. Endoscopic Therapy will boost the Portal Hypertension Drugs market. Considering Market by Drug Class, the sub-segment i.e. Vasoconstrictors will boost the Portal Hypertension Drugs market. Considering Market by End User, the sub-segment i.e. Hospital will boost the Portal Hypertension Drugs market.

In February 2021 Eli Lilly and Company had released a statement announcing the partnership with Welldoc. Lilly and Welldoc will collaborate to create an updated model of the BlueStar insulin management solution that will include glucose dosages data for several Lilly insulin analogs. The pen platform, which will include the mobile application and Lilly's connected insulin pen solutions, will be marketed by Lilly.

What Can be Explored with the Portal Hypertension Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Portal Hypertension Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Portal Hypertension Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Portal Hypertension Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Portal Hypertension Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture and Capitalist, New entrants/investors, Analysts and Strategic Business Partners, Hospitals, Clinics and End-use industries.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Portal Hypertension Drugs Market?
The Portal Hypertension Drugs market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Portal Hypertension Drugs Market?
Top performing companies in the Global Portal Hypertension Drugs market are Pfizer (United States), Sanofi (France), Bayer (Germany), Gilead Sciences (United States), Johnson & Johnson (United States), United Therapeutics Corporation (Maryland), Merck & Co (United States), GlaxoSmithKline (United Kingdom), Eli Lilly and Company (United States), AstraZeneca (United Kingdom) and Ono Pharmaceutical (Japan), to name a few.

3. What trending factors would impact Portal Hypertension Drugs Market growth most?
"Increasing Government Initiative of Supporting Orphan Drugs" is seen as one of major influencing trends for Portal Hypertension Drugs Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Type
  • Prehepatic
  • Intrahepatic
  • Posthepatic
By Treatment
  • Endoscopic Therapy
  • Surgery
  • Radiology
  • Others

By Drug Class
  • Vasoconstrictors
  • Vasodilators
  • Propranolol
  • Isosorbide
  • Others

By End User
  • Hospital
  • Clinics
  • Diagnostics Centres

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Smoking, Alcohol/Tobacco Consumption, and Other Idiopathic Condition
      • 3.2.2. Increasing Incidence of Portal Hypertension
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Drug Development
    • 3.4. Market Trends
      • 3.4.1. Increasing Government Initiative of Supporting Orphan Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Portal Hypertension Drugs, by Type, Treatment, Drug Class, End User and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Portal Hypertension Drugs (Value)
      • 5.2.1. Global Portal Hypertension Drugs by: Type (Value)
        • 5.2.1.1. Prehepatic
        • 5.2.1.2. Intrahepatic
        • 5.2.1.3. Posthepatic
      • 5.2.2. Global Portal Hypertension Drugs by: Treatment (Value)
        • 5.2.2.1. Endoscopic Therapy
        • 5.2.2.2. Surgery
        • 5.2.2.3. Radiology
        • 5.2.2.4. Others
      • 5.2.3. Global Portal Hypertension Drugs by: Drug Class (Value)
        • 5.2.3.1. Vasoconstrictors
        • 5.2.3.2. Vasodilators
        • 5.2.3.3. Propranolol
        • 5.2.3.4. Isosorbide
        • 5.2.3.5. Others
      • 5.2.4. Global Portal Hypertension Drugs by: End User (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Clinics
        • 5.2.4.3. Diagnostics Centres
      • 5.2.5. Global Portal Hypertension Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Portal Hypertension Drugs (Volume)
      • 5.3.1. Global Portal Hypertension Drugs by: Type (Volume)
        • 5.3.1.1. Prehepatic
        • 5.3.1.2. Intrahepatic
        • 5.3.1.3. Posthepatic
      • 5.3.2. Global Portal Hypertension Drugs by: Treatment (Volume)
        • 5.3.2.1. Endoscopic Therapy
        • 5.3.2.2. Surgery
        • 5.3.2.3. Radiology
        • 5.3.2.4. Others
      • 5.3.3. Global Portal Hypertension Drugs by: Drug Class (Volume)
        • 5.3.3.1. Vasoconstrictors
        • 5.3.3.2. Vasodilators
        • 5.3.3.3. Propranolol
        • 5.3.3.4. Isosorbide
        • 5.3.3.5. Others
      • 5.3.4. Global Portal Hypertension Drugs by: End User (Volume)
        • 5.3.4.1. Hospital
        • 5.3.4.2. Clinics
        • 5.3.4.3. Diagnostics Centres
      • 5.3.5. Global Portal Hypertension Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Australia
          • 5.3.5.2.6. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Portal Hypertension Drugs (Price)
      • 5.4.1. Global Portal Hypertension Drugs by: Type (Price)
  • 6. Portal Hypertension Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Gilead Sciences (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. United Therapeutics Corporation (Maryland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Ono Pharmaceutical (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Portal Hypertension Drugs Sale, by Type, Treatment, Drug Class, End User and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Portal Hypertension Drugs (Value)
      • 7.2.1. Global Portal Hypertension Drugs by: Type (Value)
        • 7.2.1.1. Prehepatic
        • 7.2.1.2. Intrahepatic
        • 7.2.1.3. Posthepatic
      • 7.2.2. Global Portal Hypertension Drugs by: Treatment (Value)
        • 7.2.2.1. Endoscopic Therapy
        • 7.2.2.2. Surgery
        • 7.2.2.3. Radiology
        • 7.2.2.4. Others
      • 7.2.3. Global Portal Hypertension Drugs by: Drug Class (Value)
        • 7.2.3.1. Vasoconstrictors
        • 7.2.3.2. Vasodilators
        • 7.2.3.3. Propranolol
        • 7.2.3.4. Isosorbide
        • 7.2.3.5. Others
      • 7.2.4. Global Portal Hypertension Drugs by: End User (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Clinics
        • 7.2.4.3. Diagnostics Centres
      • 7.2.5. Global Portal Hypertension Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Portal Hypertension Drugs (Volume)
      • 7.3.1. Global Portal Hypertension Drugs by: Type (Volume)
        • 7.3.1.1. Prehepatic
        • 7.3.1.2. Intrahepatic
        • 7.3.1.3. Posthepatic
      • 7.3.2. Global Portal Hypertension Drugs by: Treatment (Volume)
        • 7.3.2.1. Endoscopic Therapy
        • 7.3.2.2. Surgery
        • 7.3.2.3. Radiology
        • 7.3.2.4. Others
      • 7.3.3. Global Portal Hypertension Drugs by: Drug Class (Volume)
        • 7.3.3.1. Vasoconstrictors
        • 7.3.3.2. Vasodilators
        • 7.3.3.3. Propranolol
        • 7.3.3.4. Isosorbide
        • 7.3.3.5. Others
      • 7.3.4. Global Portal Hypertension Drugs by: End User (Volume)
        • 7.3.4.1. Hospital
        • 7.3.4.2. Clinics
        • 7.3.4.3. Diagnostics Centres
      • 7.3.5. Global Portal Hypertension Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Australia
          • 7.3.5.2.6. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Portal Hypertension Drugs (Price)
      • 7.4.1. Global Portal Hypertension Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Portal Hypertension Drugs: by Type(USD Million)
  • Table 2. Portal Hypertension Drugs Prehepatic , by Region USD Million (2015-2020)
  • Table 3. Portal Hypertension Drugs Intrahepatic , by Region USD Million (2015-2020)
  • Table 4. Portal Hypertension Drugs Posthepatic , by Region USD Million (2015-2020)
  • Table 5. Portal Hypertension Drugs: by Treatment(USD Million)
  • Table 6. Portal Hypertension Drugs Endoscopic Therapy , by Region USD Million (2015-2020)
  • Table 7. Portal Hypertension Drugs Surgery , by Region USD Million (2015-2020)
  • Table 8. Portal Hypertension Drugs Radiology , by Region USD Million (2015-2020)
  • Table 9. Portal Hypertension Drugs Others , by Region USD Million (2015-2020)
  • Table 10. Portal Hypertension Drugs: by Drug Class(USD Million)
  • Table 11. Portal Hypertension Drugs Vasoconstrictors , by Region USD Million (2015-2020)
  • Table 12. Portal Hypertension Drugs Vasodilators , by Region USD Million (2015-2020)
  • Table 13. Portal Hypertension Drugs Propranolol , by Region USD Million (2015-2020)
  • Table 14. Portal Hypertension Drugs Isosorbide , by Region USD Million (2015-2020)
  • Table 15. Portal Hypertension Drugs Others , by Region USD Million (2015-2020)
  • Table 16. Portal Hypertension Drugs: by End User(USD Million)
  • Table 17. Portal Hypertension Drugs Hospital , by Region USD Million (2015-2020)
  • Table 18. Portal Hypertension Drugs Clinics , by Region USD Million (2015-2020)
  • Table 19. Portal Hypertension Drugs Diagnostics Centres , by Region USD Million (2015-2020)
  • Table 20. South America Portal Hypertension Drugs, by Country USD Million (2015-2020)
  • Table 21. South America Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 22. South America Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 23. South America Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 24. South America Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 25. Brazil Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 26. Brazil Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 27. Brazil Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 28. Brazil Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 29. Argentina Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 30. Argentina Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 31. Argentina Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 32. Argentina Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 33. Rest of South America Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 34. Rest of South America Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 35. Rest of South America Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 36. Rest of South America Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 37. Asia Pacific Portal Hypertension Drugs, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 39. Asia Pacific Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 40. Asia Pacific Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 41. Asia Pacific Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 42. China Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 43. China Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 44. China Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 45. China Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 46. Japan Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 47. Japan Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 48. Japan Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 49. Japan Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 50. India Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 51. India Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 52. India Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 53. India Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 54. South Korea Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 55. South Korea Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 56. South Korea Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 57. South Korea Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 58. Australia Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 59. Australia Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 60. Australia Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 61. Australia Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 66. Europe Portal Hypertension Drugs, by Country USD Million (2015-2020)
  • Table 67. Europe Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 68. Europe Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 69. Europe Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 70. Europe Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 71. Germany Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 72. Germany Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 73. Germany Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 74. Germany Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 75. France Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 76. France Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 77. France Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 78. France Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 79. Italy Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 80. Italy Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 81. Italy Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 82. Italy Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 83. United Kingdom Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 84. United Kingdom Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 85. United Kingdom Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 86. United Kingdom Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 87. Netherlands Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 88. Netherlands Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 89. Netherlands Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 90. Netherlands Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 91. Rest of Europe Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 92. Rest of Europe Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 93. Rest of Europe Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 94. Rest of Europe Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 95. MEA Portal Hypertension Drugs, by Country USD Million (2015-2020)
  • Table 96. MEA Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 97. MEA Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 98. MEA Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 99. MEA Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 100. Middle East Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 101. Middle East Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 102. Middle East Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 103. Middle East Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 104. Africa Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 105. Africa Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 106. Africa Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 107. Africa Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 108. North America Portal Hypertension Drugs, by Country USD Million (2015-2020)
  • Table 109. North America Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 110. North America Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 111. North America Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 112. North America Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 113. United States Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 114. United States Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 115. United States Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 116. United States Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 117. Canada Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 118. Canada Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 119. Canada Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 120. Canada Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 121. Mexico Portal Hypertension Drugs, by Type USD Million (2015-2020)
  • Table 122. Mexico Portal Hypertension Drugs, by Treatment USD Million (2015-2020)
  • Table 123. Mexico Portal Hypertension Drugs, by Drug Class USD Million (2015-2020)
  • Table 124. Mexico Portal Hypertension Drugs, by End User USD Million (2015-2020)
  • Table 125. Portal Hypertension Drugs Sales: by Type(K-Unit)
  • Table 126. Portal Hypertension Drugs Sales Prehepatic , by Region K-Unit (2015-2020)
  • Table 127. Portal Hypertension Drugs Sales Intrahepatic , by Region K-Unit (2015-2020)
  • Table 128. Portal Hypertension Drugs Sales Posthepatic , by Region K-Unit (2015-2020)
  • Table 129. Portal Hypertension Drugs Sales: by Treatment(K-Unit)
  • Table 130. Portal Hypertension Drugs Sales Endoscopic Therapy , by Region K-Unit (2015-2020)
  • Table 131. Portal Hypertension Drugs Sales Surgery , by Region K-Unit (2015-2020)
  • Table 132. Portal Hypertension Drugs Sales Radiology , by Region K-Unit (2015-2020)
  • Table 133. Portal Hypertension Drugs Sales Others , by Region K-Unit (2015-2020)
  • Table 134. Portal Hypertension Drugs Sales: by Drug Class(K-Unit)
  • Table 135. Portal Hypertension Drugs Sales Vasoconstrictors , by Region K-Unit (2015-2020)
  • Table 136. Portal Hypertension Drugs Sales Vasodilators , by Region K-Unit (2015-2020)
  • Table 137. Portal Hypertension Drugs Sales Propranolol , by Region K-Unit (2015-2020)
  • Table 138. Portal Hypertension Drugs Sales Isosorbide , by Region K-Unit (2015-2020)
  • Table 139. Portal Hypertension Drugs Sales Others , by Region K-Unit (2015-2020)
  • Table 140. Portal Hypertension Drugs Sales: by End User(K-Unit)
  • Table 141. Portal Hypertension Drugs Sales Hospital , by Region K-Unit (2015-2020)
  • Table 142. Portal Hypertension Drugs Sales Clinics , by Region K-Unit (2015-2020)
  • Table 143. Portal Hypertension Drugs Sales Diagnostics Centres , by Region K-Unit (2015-2020)
  • Table 144. South America Portal Hypertension Drugs Sales, by Country K-Unit (2015-2020)
  • Table 145. South America Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 146. South America Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 147. South America Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 148. South America Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 149. Brazil Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 150. Brazil Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 151. Brazil Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 152. Brazil Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 153. Argentina Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 154. Argentina Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 155. Argentina Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 156. Argentina Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 157. Rest of South America Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 158. Rest of South America Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 159. Rest of South America Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 160. Rest of South America Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 161. Asia Pacific Portal Hypertension Drugs Sales, by Country K-Unit (2015-2020)
  • Table 162. Asia Pacific Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 163. Asia Pacific Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 164. Asia Pacific Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 165. Asia Pacific Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 166. China Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 167. China Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 168. China Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 169. China Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 170. Japan Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 171. Japan Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 172. Japan Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 173. Japan Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 174. India Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 175. India Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 176. India Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 177. India Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 178. South Korea Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 179. South Korea Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 180. South Korea Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 181. South Korea Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 182. Australia Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 183. Australia Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 184. Australia Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 185. Australia Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 186. Rest of Asia-Pacific Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 187. Rest of Asia-Pacific Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 188. Rest of Asia-Pacific Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 189. Rest of Asia-Pacific Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 190. Europe Portal Hypertension Drugs Sales, by Country K-Unit (2015-2020)
  • Table 191. Europe Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 192. Europe Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 193. Europe Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 194. Europe Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 195. Germany Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 196. Germany Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 197. Germany Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 198. Germany Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 199. France Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 200. France Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 201. France Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 202. France Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 203. Italy Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 204. Italy Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 205. Italy Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 206. Italy Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 207. United Kingdom Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 208. United Kingdom Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 209. United Kingdom Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 210. United Kingdom Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 211. Netherlands Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 212. Netherlands Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 213. Netherlands Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 214. Netherlands Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 215. Rest of Europe Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 216. Rest of Europe Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 217. Rest of Europe Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 218. Rest of Europe Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 219. MEA Portal Hypertension Drugs Sales, by Country K-Unit (2015-2020)
  • Table 220. MEA Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 221. MEA Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 222. MEA Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 223. MEA Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 224. Middle East Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 225. Middle East Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 226. Middle East Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 227. Middle East Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 228. Africa Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 229. Africa Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 230. Africa Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 231. Africa Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 232. North America Portal Hypertension Drugs Sales, by Country K-Unit (2015-2020)
  • Table 233. North America Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 234. North America Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 235. North America Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 236. North America Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 237. United States Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 238. United States Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 239. United States Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 240. United States Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 241. Canada Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 242. Canada Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 243. Canada Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 244. Canada Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 245. Mexico Portal Hypertension Drugs Sales, by Type K-Unit (2015-2020)
  • Table 246. Mexico Portal Hypertension Drugs Sales, by Treatment K-Unit (2015-2020)
  • Table 247. Mexico Portal Hypertension Drugs Sales, by Drug Class K-Unit (2015-2020)
  • Table 248. Mexico Portal Hypertension Drugs Sales, by End User K-Unit (2015-2020)
  • Table 249. Portal Hypertension Drugs: by Type(USD/Units)
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Portal Hypertension Drugs: by Type(USD Million)
  • Table 262. Portal Hypertension Drugs Prehepatic , by Region USD Million (2021-2026)
  • Table 263. Portal Hypertension Drugs Intrahepatic , by Region USD Million (2021-2026)
  • Table 264. Portal Hypertension Drugs Posthepatic , by Region USD Million (2021-2026)
  • Table 265. Portal Hypertension Drugs: by Treatment(USD Million)
  • Table 266. Portal Hypertension Drugs Endoscopic Therapy , by Region USD Million (2021-2026)
  • Table 267. Portal Hypertension Drugs Surgery , by Region USD Million (2021-2026)
  • Table 268. Portal Hypertension Drugs Radiology , by Region USD Million (2021-2026)
  • Table 269. Portal Hypertension Drugs Others , by Region USD Million (2021-2026)
  • Table 270. Portal Hypertension Drugs: by Drug Class(USD Million)
  • Table 271. Portal Hypertension Drugs Vasoconstrictors , by Region USD Million (2021-2026)
  • Table 272. Portal Hypertension Drugs Vasodilators , by Region USD Million (2021-2026)
  • Table 273. Portal Hypertension Drugs Propranolol , by Region USD Million (2021-2026)
  • Table 274. Portal Hypertension Drugs Isosorbide , by Region USD Million (2021-2026)
  • Table 275. Portal Hypertension Drugs Others , by Region USD Million (2021-2026)
  • Table 276. Portal Hypertension Drugs: by End User(USD Million)
  • Table 277. Portal Hypertension Drugs Hospital , by Region USD Million (2021-2026)
  • Table 278. Portal Hypertension Drugs Clinics , by Region USD Million (2021-2026)
  • Table 279. Portal Hypertension Drugs Diagnostics Centres , by Region USD Million (2021-2026)
  • Table 280. South America Portal Hypertension Drugs, by Country USD Million (2021-2026)
  • Table 281. South America Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 282. South America Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 283. South America Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 284. South America Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 285. Brazil Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 286. Brazil Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 287. Brazil Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 288. Brazil Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 289. Argentina Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 290. Argentina Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 291. Argentina Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 292. Argentina Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 293. Rest of South America Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 294. Rest of South America Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 295. Rest of South America Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 296. Rest of South America Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 297. Asia Pacific Portal Hypertension Drugs, by Country USD Million (2021-2026)
  • Table 298. Asia Pacific Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 299. Asia Pacific Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 300. Asia Pacific Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 301. Asia Pacific Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 302. China Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 303. China Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 304. China Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 305. China Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 306. Japan Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 307. Japan Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 308. Japan Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 309. Japan Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 310. India Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 311. India Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 312. India Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 313. India Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 314. South Korea Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 315. South Korea Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 316. South Korea Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 317. South Korea Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 318. Australia Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 319. Australia Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 320. Australia Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 321. Australia Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 322. Rest of Asia-Pacific Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 323. Rest of Asia-Pacific Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 324. Rest of Asia-Pacific Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 325. Rest of Asia-Pacific Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 326. Europe Portal Hypertension Drugs, by Country USD Million (2021-2026)
  • Table 327. Europe Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 328. Europe Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 329. Europe Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 330. Europe Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 331. Germany Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 332. Germany Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 333. Germany Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 334. Germany Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 335. France Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 336. France Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 337. France Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 338. France Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 339. Italy Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 340. Italy Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 341. Italy Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 342. Italy Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 343. United Kingdom Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 344. United Kingdom Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 345. United Kingdom Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 346. United Kingdom Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 347. Netherlands Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 348. Netherlands Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 349. Netherlands Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 350. Netherlands Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 351. Rest of Europe Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 352. Rest of Europe Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 353. Rest of Europe Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 354. Rest of Europe Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 355. MEA Portal Hypertension Drugs, by Country USD Million (2021-2026)
  • Table 356. MEA Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 357. MEA Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 358. MEA Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 359. MEA Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 360. Middle East Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 361. Middle East Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 362. Middle East Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 363. Middle East Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 364. Africa Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 365. Africa Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 366. Africa Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 367. Africa Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 368. North America Portal Hypertension Drugs, by Country USD Million (2021-2026)
  • Table 369. North America Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 370. North America Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 371. North America Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 372. North America Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 373. United States Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 374. United States Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 375. United States Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 376. United States Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 377. Canada Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 378. Canada Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 379. Canada Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 380. Canada Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 381. Mexico Portal Hypertension Drugs, by Type USD Million (2021-2026)
  • Table 382. Mexico Portal Hypertension Drugs, by Treatment USD Million (2021-2026)
  • Table 383. Mexico Portal Hypertension Drugs, by Drug Class USD Million (2021-2026)
  • Table 384. Mexico Portal Hypertension Drugs, by End User USD Million (2021-2026)
  • Table 385. Portal Hypertension Drugs Sales: by Type(K-Unit)
  • Table 386. Portal Hypertension Drugs Sales Prehepatic , by Region K-Unit (2021-2026)
  • Table 387. Portal Hypertension Drugs Sales Intrahepatic , by Region K-Unit (2021-2026)
  • Table 388. Portal Hypertension Drugs Sales Posthepatic , by Region K-Unit (2021-2026)
  • Table 389. Portal Hypertension Drugs Sales: by Treatment(K-Unit)
  • Table 390. Portal Hypertension Drugs Sales Endoscopic Therapy , by Region K-Unit (2021-2026)
  • Table 391. Portal Hypertension Drugs Sales Surgery , by Region K-Unit (2021-2026)
  • Table 392. Portal Hypertension Drugs Sales Radiology , by Region K-Unit (2021-2026)
  • Table 393. Portal Hypertension Drugs Sales Others , by Region K-Unit (2021-2026)
  • Table 394. Portal Hypertension Drugs Sales: by Drug Class(K-Unit)
  • Table 395. Portal Hypertension Drugs Sales Vasoconstrictors , by Region K-Unit (2021-2026)
  • Table 396. Portal Hypertension Drugs Sales Vasodilators , by Region K-Unit (2021-2026)
  • Table 397. Portal Hypertension Drugs Sales Propranolol , by Region K-Unit (2021-2026)
  • Table 398. Portal Hypertension Drugs Sales Isosorbide , by Region K-Unit (2021-2026)
  • Table 399. Portal Hypertension Drugs Sales Others , by Region K-Unit (2021-2026)
  • Table 400. Portal Hypertension Drugs Sales: by End User(K-Unit)
  • Table 401. Portal Hypertension Drugs Sales Hospital , by Region K-Unit (2021-2026)
  • Table 402. Portal Hypertension Drugs Sales Clinics , by Region K-Unit (2021-2026)
  • Table 403. Portal Hypertension Drugs Sales Diagnostics Centres , by Region K-Unit (2021-2026)
  • Table 404. South America Portal Hypertension Drugs Sales, by Country K-Unit (2021-2026)
  • Table 405. South America Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 406. South America Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 407. South America Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 408. South America Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 409. Brazil Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 410. Brazil Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 411. Brazil Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 412. Brazil Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 413. Argentina Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 414. Argentina Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 415. Argentina Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 416. Argentina Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 417. Rest of South America Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 418. Rest of South America Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 419. Rest of South America Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 420. Rest of South America Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 421. Asia Pacific Portal Hypertension Drugs Sales, by Country K-Unit (2021-2026)
  • Table 422. Asia Pacific Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 423. Asia Pacific Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 424. Asia Pacific Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 425. Asia Pacific Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 426. China Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 427. China Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 428. China Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 429. China Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 430. Japan Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 431. Japan Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 432. Japan Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 433. Japan Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 434. India Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 435. India Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 436. India Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 437. India Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 438. South Korea Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 439. South Korea Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 440. South Korea Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 441. South Korea Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 442. Australia Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 443. Australia Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 444. Australia Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 445. Australia Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 446. Rest of Asia-Pacific Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 447. Rest of Asia-Pacific Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 448. Rest of Asia-Pacific Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 449. Rest of Asia-Pacific Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 450. Europe Portal Hypertension Drugs Sales, by Country K-Unit (2021-2026)
  • Table 451. Europe Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 452. Europe Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 453. Europe Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 454. Europe Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 455. Germany Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 456. Germany Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 457. Germany Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 458. Germany Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 459. France Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 460. France Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 461. France Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 462. France Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 463. Italy Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 464. Italy Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 465. Italy Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 466. Italy Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 467. United Kingdom Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 468. United Kingdom Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 469. United Kingdom Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 470. United Kingdom Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 471. Netherlands Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 472. Netherlands Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 473. Netherlands Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 474. Netherlands Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 475. Rest of Europe Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 476. Rest of Europe Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 477. Rest of Europe Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 478. Rest of Europe Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 479. MEA Portal Hypertension Drugs Sales, by Country K-Unit (2021-2026)
  • Table 480. MEA Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 481. MEA Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 482. MEA Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 483. MEA Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 484. Middle East Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 485. Middle East Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 486. Middle East Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 487. Middle East Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 488. Africa Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 489. Africa Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 490. Africa Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 491. Africa Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 492. North America Portal Hypertension Drugs Sales, by Country K-Unit (2021-2026)
  • Table 493. North America Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 494. North America Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 495. North America Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 496. North America Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 497. United States Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 498. United States Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 499. United States Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 500. United States Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 501. Canada Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 502. Canada Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 503. Canada Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 504. Canada Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 505. Mexico Portal Hypertension Drugs Sales, by Type K-Unit (2021-2026)
  • Table 506. Mexico Portal Hypertension Drugs Sales, by Treatment K-Unit (2021-2026)
  • Table 507. Mexico Portal Hypertension Drugs Sales, by Drug Class K-Unit (2021-2026)
  • Table 508. Mexico Portal Hypertension Drugs Sales, by End User K-Unit (2021-2026)
  • Table 509. Portal Hypertension Drugs: by Type(USD/Units)
  • Table 510. Research Programs/Design for This Report
  • Table 511. Key Data Information from Secondary Sources
  • Table 512. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Portal Hypertension Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Portal Hypertension Drugs: by Treatment USD Million (2015-2020)
  • Figure 6. Global Portal Hypertension Drugs: by Drug Class USD Million (2015-2020)
  • Figure 7. Global Portal Hypertension Drugs: by End User USD Million (2015-2020)
  • Figure 8. South America Portal Hypertension Drugs Share (%), by Country
  • Figure 9. Asia Pacific Portal Hypertension Drugs Share (%), by Country
  • Figure 10. Europe Portal Hypertension Drugs Share (%), by Country
  • Figure 11. MEA Portal Hypertension Drugs Share (%), by Country
  • Figure 12. North America Portal Hypertension Drugs Share (%), by Country
  • Figure 13. Global Portal Hypertension Drugs: by Type K-Unit (2015-2020)
  • Figure 14. Global Portal Hypertension Drugs: by Treatment K-Unit (2015-2020)
  • Figure 15. Global Portal Hypertension Drugs: by Drug Class K-Unit (2015-2020)
  • Figure 16. Global Portal Hypertension Drugs: by End User K-Unit (2015-2020)
  • Figure 17. South America Portal Hypertension Drugs Share (%), by Country
  • Figure 18. Asia Pacific Portal Hypertension Drugs Share (%), by Country
  • Figure 19. Europe Portal Hypertension Drugs Share (%), by Country
  • Figure 20. MEA Portal Hypertension Drugs Share (%), by Country
  • Figure 21. North America Portal Hypertension Drugs Share (%), by Country
  • Figure 22. Global Portal Hypertension Drugs: by Type USD/Units (2015-2020)
  • Figure 23. Global Portal Hypertension Drugs share by Players 2020 (%)
  • Figure 24. Global Portal Hypertension Drugs share by Players (Top 3) 2020(%)
  • Figure 25. Global Portal Hypertension Drugs share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer (United States) Revenue: by Geography 2020
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2020
  • Figure 31. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Bayer (Germany) Revenue: by Geography 2020
  • Figure 33. Gilead Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 34. Gilead Sciences (United States) Revenue: by Geography 2020
  • Figure 35. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 37. United Therapeutics Corporation (Maryland) Revenue, Net Income and Gross profit
  • Figure 38. United Therapeutics Corporation (Maryland) Revenue: by Geography 2020
  • Figure 39. Merck & Co (United States) Revenue, Net Income and Gross profit
  • Figure 40. Merck & Co (United States) Revenue: by Geography 2020
  • Figure 41. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 42. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 43. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 44. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 45. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 46. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 47. Ono Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 48. Ono Pharmaceutical (Japan) Revenue: by Geography 2020
  • Figure 49. Global Portal Hypertension Drugs: by Type USD Million (2021-2026)
  • Figure 50. Global Portal Hypertension Drugs: by Treatment USD Million (2021-2026)
  • Figure 51. Global Portal Hypertension Drugs: by Drug Class USD Million (2021-2026)
  • Figure 52. Global Portal Hypertension Drugs: by End User USD Million (2021-2026)
  • Figure 53. South America Portal Hypertension Drugs Share (%), by Country
  • Figure 54. Asia Pacific Portal Hypertension Drugs Share (%), by Country
  • Figure 55. Europe Portal Hypertension Drugs Share (%), by Country
  • Figure 56. MEA Portal Hypertension Drugs Share (%), by Country
  • Figure 57. North America Portal Hypertension Drugs Share (%), by Country
  • Figure 58. Global Portal Hypertension Drugs: by Type K-Unit (2021-2026)
  • Figure 59. Global Portal Hypertension Drugs: by Treatment K-Unit (2021-2026)
  • Figure 60. Global Portal Hypertension Drugs: by Drug Class K-Unit (2021-2026)
  • Figure 61. Global Portal Hypertension Drugs: by End User K-Unit (2021-2026)
  • Figure 62. South America Portal Hypertension Drugs Share (%), by Country
  • Figure 63. Asia Pacific Portal Hypertension Drugs Share (%), by Country
  • Figure 64. Europe Portal Hypertension Drugs Share (%), by Country
  • Figure 65. MEA Portal Hypertension Drugs Share (%), by Country
  • Figure 66. North America Portal Hypertension Drugs Share (%), by Country
  • Figure 67. Global Portal Hypertension Drugs: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Pfizer (United States)
  • Sanofi (France)
  • Bayer (Germany)
  • Gilead Sciences (United States)
  • Johnson & Johnson (United States)
  • United Therapeutics Corporation (Maryland)
  • Merck & Co (United States)
  • GlaxoSmithKline (United Kingdom)
  • Eli Lilly and Company (United States)
  • AstraZeneca (United Kingdom)
  • Ono Pharmaceutical (Japan)
Additional players considered in the study are as follows:
Chiasma (United States) , Acceleron Pharma (United States
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation